Roeland Lameris

Roeland Lameris

Auto-generated profile, based on publicly available information

Roeland Lameris

Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in Cell Reports Medicine
Verified
Journal Article
Open access
RLRoeland Lameris
Roeland Lameris
JRJurjen M. Ruben
Jurjen M. Ruben
VIVictoria Iglesias-Guimarais
Victoria Iglesias-Guimarais
MJMilon de Jong
Milon de Jong
MVMyrthe Veth
Myrthe Veth
HVHans van der Vliet
Hans van der Vliet
Bispecific T cell engagers (bsTCEs) hold great promise for cancer treatment but face challenges due to the induction of cytokine release syndrome (CRS), on-target off-tumor toxicity, and the engagement of immunosuppressive regulatory T cells that limit efficacy. The development of Vγ9Vδ2-T cell engagers may overcome these challenges by combining high therapeutic efficacy with limited toxicity. By linking a CD1d-specific single-domain antibody (VHH) to a Vδ2-TCR-specific VHH, we create a bsTCE with trispecific properties, which engages not only Vγ9Vδ2-T cells but also type 1 NKT cells to CD1d+ tumors and triggers robust proinflammatory cytokine production, effector cell expansion, and target cell lysis in vitro. We show that CD1d is expressed by the majority of patient MM, (myelo)monocytic AML, and CLL cells and that the bsTCE triggers type 1 NKT and Vγ9Vδ2-T cell-mediated antitumor activity against these patient tumor cells and improves survival in in vivo AML, MM, and T-ALL mouse models. Evaluation of a surrogate CD1d-γδ bsTCE in NHPs shows Vγ9Vδ2-T cell engagement and excellent tolerability. Based on these results, CD1d-Vδ2 bsTCE (LAVA-051) is now evaluated in a phase 1/2a study in patients with therapy refractory CLL, MM, or AML.

1 December 2023 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
RLRoeland Lameris
Roeland Lameris
ASAdam Shahine
Adam Shahine
MVMyrthe Veth
Myrthe Veth
BWBart Westerman
Bart Westerman
DGDale I Godfrey
Dale I Godfrey
HVHans van der Vliet
Hans van der Vliet
Background: CD1d is a monomorphic major histocompatibility complex class I-like molecule that presents lipid antigens to distinct T-cell subsets and can be expressed by various malignancies. Antibody-mediated targeting of CD1d on multiple myeloma cells was reported to induce apoptosis and could therefore constitute a novel therapeutic approach. Methods: To determine how a CD1d-specific single-domain antibody (VHH) enhances binding of the early apoptosis marker annexin V to CD1d+ tumor cells we use in vitro cell-based assays and CRISPR-Cas9-mediated gene editing, and to determine the structure of the VHH1D17-CD1d(endogenous lipid) complex we use X-ray crystallography. Results: Anti-CD1d VHH1D17 strongly enhances annexin V binding to CD1d+ tumor cells but this does not reflect induction of apoptosis. Instead, we show that VHH1D17 enhances presentation of phosphatidylserine (PS) in CD1d and that this is saposin dependent. The crystal structure of the VHH1D17-CD1d(endogenous lipid) complex demonstrates that VHH1D17 binds the A′-pocket of CD1d, leaving the lipid headgroup solvent exposed, and has an electro-negatively charged patch which could be involved in the enhanced PS presentation by CD1d. Presentation of PS in CD1d does not trigger phagocytosis but leads to greatly enhanced binding of T-cell immunoglobulin and mucin domain containing molecules (TIM)-1 to TIM-3, TIM-4 and induces TIM-3 signaling. Conclusion: Our findings reveal the existence of an immune modulatory CD1d(PS)-TIM axis with potentially unexpected implications for immune regulation in both physiological and pathological conditions.

4 April 2023
Verified
Other
Open access
IWIris de Weerdt
Iris de Weerdt
RLRoeland Lameris
Roeland Lameris
GSGeorge L. Scheffer
George L. Scheffer
JVJana Vree
Jana Vree
RBRenate de Boer
Renate de Boer
HVHans van der Vliet
Hans van der Vliet
Supplementary Tables 1-2 and Figure legends

4 April 2023
Verified
Other
Open access
IWIris de Weerdt
Iris de Weerdt
RLRoeland Lameris
Roeland Lameris
GSGeorge L. Scheffer
George L. Scheffer
JVJana Vree
Jana Vree
RBRenate de Boer
Renate de Boer
HVHans van der Vliet
Hans van der Vliet

28 June 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
MJMilon de Jong
Milon de Jong
MVMyrthe Veth
Myrthe Veth
TBTereza Brachtlová
Tereza Brachtlová
LKLisa A King
Lisa A King
JSJosé Saura-Esteller
José Saura-Esteller
HVHans van der Vliet
Hans van der Vliet
Background: Vγ9Vδ2-T cells form a conserved T-cell subset known for its potent intrinsic antitumor activity and versatility in recognizing diverse cancer types independently of the major histocompatibility complex. Previously, we reported the preclinical activity of a bispecific T-cell engager (bsTCE) specific for both CD1d and the Vδ2-TCR that engaged both Vγ9Vδ2-T and type 1 natural killer T cells to CD1d-expressing hematological malignancies, including multiple myeloma (MM) and acute myeloid leukemia (AML). Here, we evaluated whether various standard-of-care drugs for patients with MM and AML/myelodysplastic syndromes (MDS) affected the in vitro antitumor activity of CD1d-Vδ2 bsTCE-activated Vγ9Vδ2-T cells. Methods: MM and AML/MDS standard-of-care drugs were tested for antagonistic, additive, or synergistic effects on CD1d-Vδ2 bsTCE-induced and Vγ9Vδ2-T cell-mediated tumor cell lysis. Based on observed synergy, the immunomodulatory drug (IMiD) lenalidomide was studied in more detail, exploring effects on Vγ9Vδ2-T cell proliferation, phenotype, cytokine profile, and cytolytic activity, as well as its mechanism of action, using healthy donor peripheral blood mononuclear cells (PBMC) and MDS patient PBMC and bone marrow samples. Results: Lenalidomide exerted synergistic activity on CD1d-Vδ2 bsTCE-triggered Vγ9Vδ2-T cell antitumor activity and was found to substantially enhance CD1d-Vδ2 bsTCE-induced Vγ9Vδ2-T cell activation, degranulation, T h 1-type cytokine secretion, and expansion. Stimulatory effects of lenalidomide on Vγ9Vδ2-T cell effector functions were mediated via enhanced intracellular CD28 phosphorylation, activation of Notch signaling, and interleukin-2 release. Importantly, lenalidomide facilitated otherwise absent proliferation of Vγ9Vδ2-T cells with oncolytic potential in response to CD1d-Vδ2 bsTCE exposure in MDS patient-derived bone marrow samples. Conclusion: Our findings provide a rationale to explore the combination of CD1d-Vδ2 bsTCE and the IMiD lenalidomide in patients with CD1d-expressing hematological malignancies.

4 April 2023
Verified
Other
Open access
IWIris de Weerdt
Iris de Weerdt
RLRoeland Lameris
Roeland Lameris
GSGeorge L. Scheffer
George L. Scheffer
JVJana Vree
Jana Vree
RBRenate de Boer
Renate de Boer
HVHans van der Vliet
Hans van der Vliet